Registered on ClinicalTrials
A.I. FEDIN1, V.V. ZAKHAROV2, M.M. TANASHYAN3, E.I. CHUKANOVA1, E.N. MAJIDOVA4, L.A. SCHEPANKEVICH5.6, O.D. OSTROUMOVA7
1Pirogov Russian National Research Medical University, Moscow, Russia;
2I.M. Sechenov First Moscow Medical University,
3Neurology Research Center,
4, Russia;
5Novosibirsk State Medical University, Novosibirsk
6Federal Research Center for Fundamental and Translational Medicine, Novosibirsk, Russia;
7Russian Medical Academy of Continuous Professional Education, Moscow, Russia
Place of publication:
S.S. KORSAKOV JOURNAL OF NEUROLOGY AND PSYCHIATRY, 2021, Vol. 121, No. 11
Abstract:
The aim of the study was to evaluate the efficacy and safety of sequential therapy with intravenous Mexidol and orally Mexidol FORTE 250 in patients with chronic cerebral ischemia (CCI).
Material and methods. The international multicenter, randomized, double-blind, placebo-controlled study conducted in 15 clinical centers located in the Russian Federation and the Republic of Uzbekistan included 318 patients with CCI aged 40 to 90 years. Patients were randomized into 2 groups. Patients in group 1 received Mexidol intravenously 500 mg once a day for 14 days, then Mexidol FORTE 250 was prescribed orally 250 mg 3 times a day for the next 60 days; patients in group 2 received placebo in a similar regimen. The primary efficacy criterion was the mean change in the MoCA score at the end of the study compared to the baseline level.
Results. At the end of the study, significant differences in the MoCA scale results were found between groups 1 and 2 (p
Conclusion. The validity and feasibility of the sequential use of Mexidol and Mexidol FORTE 250 in the treatment of patients with chronic cerebral ischemia (CCI) have been demonstrated.
Key words: chronic cerebral ischemia, cognitive impairment, neuropsychological testing, ethylmethylhydroxypyridine succinate, Mexidol, Mexidol FORTE 250, treatment of chronic cerebral ischemia, MEMO study.
Link to the study here
